Cyclo Therapeutics presents data from study, substudy of Trappsol Cyclo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 05 2024
0mins
Study Overview: Cyclo Therapeutics presented preliminary data from its Phase 3 study on Trappsol Cyclo for Niemann-Pick Disease Type C1 at the SSIEM Annual Symposium 2024, highlighting its comprehensive approach and focus on early intervention in young patients.
Safety and Enrollment: The study has enrolled 104 patients with a safety profile consistent with previous studies, reporting mostly mild adverse events, while the substudy aims to evaluate treatment effects over 192 weeks in very young patients, with interim results expected in H1 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
